A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease

Paused · Phase 3

Conditions studied: Dry Eye

In brief

The objectives of this study are to compare the efficacy and safety of tanfanercept ophthalmic solution 0.25% and 1.0% to vehicle for the treatment of DED.

Key facts

Study ID

NCT06400589

Run by

HanAll BioPharma Co., Ltd.

People needed

750

Starts

2024-05-01

Expected to finish

2025-08-01

Last updated by the study team

2024-05-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Are at least 18 years of age
• Provide written informed consent
• Are willing to attend all study visits and able to comply with study procedures and assessments
• Have a self-reported history of DED (OU) for at least 6 months prior to Visit 1

You may not qualify if…

• Have an uncontrolled systemic disease
• Have been exposed to an investigational drug or device within 30 days or 5 half-lives prior to Visit 1, whichever is longer

Where it is running

• HanAll Site #1 — Delray Beach, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.